Table 1.
Recently published clinical trials using combined RT and ICI for treatment of advanced hepatocellular carcinoma.
| Trial Name | Year Published |
Phase | Treatment | Patient Population | Primary End Point |
|---|---|---|---|---|---|
| CA 209-678 NCT03033446 |
2021 | II | RE + Nivolumab | Advanced HCC, Child-Pugh A | ORR |
| NCT04193696 | 2022 | II | SBRT + Camrelizumab | Advanced HCC, Child-Pugh A/B | ORR and Safety |
| START-FIT NCT03817736 |
2023 | II | TACE + SBRT + Avelumab | Advanced HCC, Child-Pugh A/B | Patients able to undergo curative treatment |
| NASIR-HCC NCT03380130 |
2022 | II | SIRT + Nivolumab | BCLC B2 tumors | Safety, ORR, and OS |
| NCT03203304* | 2023 | I | SBRT + Nivolumab or Nivolumab + ipilimumab | Advanced HCC | Dose-limiting toxicity, ORR, PFS, OS |
RE, Radioembolization; HCC, Hepatocellular Carcinoma; ORR, Objective Response Rate; SBRT, Stereotactic Body Radiation Therapy; TACE, Trans arterial Chemoembolization; SIRT, Selective Internal Radiation Therapy; OS, Overall Survival; PFS, Progression Free Survival.
*Trial stopped due to poor accrual.